Abstract:Rationale: Poor β cell proliferation is one of the detrimental factors hindering islet cell replacement therapy for patients with diabetes. Smad3 is an important transcriptional factor of TGF-β signaling and has been shown to promote diabetes by inhibiting β cell proliferation. Therefore, we hypothesize that Smad3-deficient islets may be a novel cell replacement therapy for diabetes. Methods: We examined this hypothesis in streptozocin-induced type-1 diabetic mice and type-2 diabetic db/db mice by transplanting Smad3 knockout (KO) and wild type (WT) islets under the renal capsule, respectively. The effects of Smad3KO versus WT islet replacement therapy on diabetes and diabetic kidney injury were examined. In addition, RNA-seq was applied to identify the downstream target gene underlying Smad3-regulated β cell proliferation in Smad3KO-db/db versus Smad3WT-db/db mouse islets. Results: Compared to Smad3WT islet therapy, treatment with Smad3KO islets produced a much better therapeutic effect on both type-1 and type-2 diabetes by significantly lowering serum levels of blood glucose and HbA1c and protected against diabetic kidney injuries by preventing an increase in serum creatinine and the development of proteinuria, mesangial matrix expansion, and fibrosis. These were associated with a significant increase in grafted β cell proliferation and blood insulin levels, resulting in improved glucose intolerance. Mechanistically, RNA-seq revealed that compared with Smad3WT-db/db mouse islets, deletion of Smad3 from db/db mouse islets markedly upregulated E2F3, a pivotal regulator of cell cycle G1/S entry. Further studies found that Smad3 could bind to the promoter of E2F3, and thus inhibit β cell proliferation via an E2F3-dependent mechanism as silencing E2F3 abrogated the proliferative effect on Smad3KO β cells. Conclusion: Smad3-deficient islet replacement therapy can significantly improve both type-1 and type-2 diabetes and protect against diabetic kidney injury, which is mediated by a novel mechanism of E2F3-dependent β cell proliferation.

Smad3 deficiency promotes beta cell proliferation and function in db/db mice via restoring Pax6 expression

Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism

Smad3 Promotes AKI Sensitivity in Diabetic Mice Via Interaction with P53 and Induction of NOX4-dependent ROS Production

Β-Cell Smad2 Null Mice Have Improved Β-Cell Function and Are Protected from Diet-Induced Hyperglycemia

Role of TGF-Beta Signaling in Beta Cell Proliferation and Function in Diabetes

The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic Potential

SMAD2 disruption in mouse pancreatic beta cells leads to islet hyperplasia and impaired insulin secretion due to the attenuation of ATP-sensitive K+ channel activity

AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice

Disparate Phospho-Smad2 Levels in Advanced Type 2 Diabetes Patients with Diabetic Nephropathy and Early Experimental Db/db Mouse Model.

Smad3 Deficiency Protects Mice from Obesity-Induced Podocyte Injury That Precedes Insulin Resistance

Retracted: MicroRNA‐30d Preserves Pancreatic Islet Β‐cell Function Through Negative Regulation of the JNK Signaling Pathway Via SOCS3 in Mice with Streptozotocin‐induced Diabetes Mellitus

Protection from Obesity and Diabetes by Blockade of TGF-β/Smad3 Signaling.

SMAD7 Enhances Adult Β-Cell Proliferation Without Significantly Affecting Β-Cell Function in Mice

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

MicroRNA-223 is Essential for Maintaining Functional Β-Cell Mass During Diabetes Through Inhibiting Both FOXO1 and SOX6 Pathways

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Disruption of Growth Factor Receptor–Binding Protein 10 in the Pancreas Enhances Β-Cell Proliferation and Protects Mice from Streptozotocin-Induced Β-Cell Apoptosis

Menin‐regulated Pbk controls high fat diet‐induced compensatory beta cell proliferation

Deletion of Smad3 Improves Cardiac Allograft Rejection in Mice.

Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice

SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy